Anticipated Stigma, Illness Identity, and Quality of Life in Male Hypogonadism
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorHacettepe University
About this trial
This study aims to systematically compare the levels of anticipated illness stigma and illness identity among men diagnosed with hypogonadism to those of men with other chronic endocrine conditions (e.g., diabetes mellitus, hypothyroidism, and hypertension). Furthermore, it examines whether these psychosocial variables predict quality-of-life deterioration specifically within the hypogonadism cohort.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male, aged 18 years or older.
Biochemically confirmed hypogonadism (total testosterone < 300 ng/dL with at least one clinical symptom).
Regular follow-up at the endocrinology outpatient clinic.
Fluent in reading and understanding Turkish.
Disqualifiers
Active psychiatric diagnosis (e.g., active psychosis, bipolar disorder).
Chronic inflammatory or rheumatological diseases affecting body composition (e.g., chronic kidney disease, IBD, rheumatoid arthritis, SLE, ankylosing spondylitis).
Uncontrolled co-existing endocrine conditions or severe complications (e.g., HbA1c > 8.0%, diabetic neuropathy/nephropathy/retinopathy, non-euthyroid state).
Cognitive impairment or dementia precluding questionnaire completion.
Trial population
Male patients aged 18 years and older who are routinely followed up at the endocrinology outpatient clinic of Malatya Training and Research Hospital. The population comprises two distinct subgroups: men with a biochemically confirmed diagnosis of hypogonadism and age-matched men diagnosed with other chronic endocrine or metabolic conditions (diabetes mellitus, hypertension, or hypothyroidism) without hypogonadism.
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
90 Participants
are grouped into 2 trial groupsGroup A: Hypogonadism Group (Case)
Group B: Control Group (Other Chronic Endocrine Diseases)
Trial outcomes
Primary outcomes
1
Chronic Illness Anticipated Stigma Scale (CIASS) Score
Measures anticipated stigma across three subscales (friends/family, work, healthcare workers) on a 5-point Likert scale.
Time frame
Baseline (Single session, day 1)2
Brief Illness Perception Questionnaire (Brief IPQ) Score
Assesses cognitive and emotional representations of illness. Higher total scores indicate a more threatening illness perception.
Time frame
Baseline (Single session, day 1)Secondary outcomes
1
Aging Males' Symptoms (AMS) Scale Score
Evaluates the severity of symptoms related to aging/hypogonadism across somatic, psychological, and sexual domains.
Time frame
Baseline (Single session, day 1)2
Hospital Anxiety and Depression Scale (HADS) Score
Measures anxiety and depression symptom severity via 14 items (7 anxiety, 7 depression).
Time frame
Baseline (Single session, day 1)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Hacettepe University
Lead sponsor
Bingol University
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: